Medimmune Inc Watch

EX-10.27

from 10-K 61 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Asset Purchase Agreement Between Medimmune, Inc., as Seller, and Zlb Behring AG, as Purchaser, Dated as of November 8, 2006

12/34/56

EX-10.1

from 10-Q 88 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Collaboration Agreement Between Medimmune, Inc. and Infinity Pharmaceuticals, Inc. Dated as of August 25, 2006 Collaboration Agreement

12/34/56

EX-10

from 10-Q 17 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Lehman Brothers Otc Derivatives Inc. (“Dealer”) Represented by Lehman Brothers Inc. (“Agent”) as Its Agent, and Medimmune, Inc. (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Is Sent on Behalf of Both Dealer and Lehman Brothers Inc. Lehman Brothers Otc Derivatives Inc. Is Not a Member of the Securities Investor Protection Corporation

12/34/56

EX-10

from 10-Q 17 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Lehman Brothers Otc Derivatives Inc. (“Dealer”) Represented by Lehman Brothers Inc. (“Agent”) as Its Agent, and Medimmune, Inc. (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Is Sent on Behalf of Both Dealer and Lehman Brothers Inc. Lehman Brothers Otc Derivatives Inc. Is Not a Member of the Securities Investor Protection Corporation

12/34/56

EX-10

from 10-Q 15 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Ubs AG, London Branch (“Dealer”) Represented by Ubs Securities LLC (“Agent”) as Its Agent, and Medimmune, Inc. (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below

12/34/56

EX-10

from 10-Q 15 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Ubs AG, London Branch (“Dealer”) Represented by Ubs Securities LLC (“Agent”) as Its Agent, and Medimmune, Inc. (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below

12/34/56

EX-10

from 10-Q 3 pages Re: Amendment to Issuer Warrant Transaction

12/34/56

EX-10

from 10-Q 3 pages Re: Amendment to Issuer Warrant Transaction

12/34/56

EX-10

from 10-Q 3 pages Section 2. Amendment to the Confirmation

12/34/56

EX-10

from 10-Q 3 pages Section 2. Amendment to the Confirmation

12/34/56

EX-10

from 10-Q 15 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Lehman Brothers Otc Derivatives Inc. (“Dealer”) Represented by Lehman Brothers Inc. (“Agent”) as Its Agent, and Medimmune, Inc. (“Issuer”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Is Sent on Behalf of Both Dealer and Lehman Brothers Inc. Lehman Brothers Otc Derivatives Inc. Is Not a Member of the Securities Investor Protection Corporation

12/34/56

EX-10

from 10-Q 15 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Lehman Brothers Otc Derivatives Inc. (“Dealer”) Represented by Lehman Brothers Inc. (“Agent”) as Its Agent, and Medimmune, Inc. (“Issuer”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Is Sent on Behalf of Both Dealer and Lehman Brothers Inc. Lehman Brothers Otc Derivatives Inc. Is Not a Member of the Securities Investor Protection Corporation

12/34/56

EX-10

from 10-Q 15 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Ubs AG, London Branch (“Dealer”) Represented by Ubs Securities LLC (“Agent”) as Its Agent, and Medimmune, Inc. (“Issuer”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below

12/34/56

EX-10

from 10-Q 15 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Ubs AG, London Branch (“Dealer”) Represented by Ubs Securities LLC (“Agent”) as Its Agent, and Medimmune, Inc. (“Issuer”). This Communication Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below

12/34/56

EX-10

from 10-Q 23 pages Employment Agreement

12/34/56

EX-10

from 10-Q 8 pages Third Amendment to Co-Promotion Agreement

12/34/56

EX-10.2

from 10-Q 6 pages Patent Licence (Adair Patent Rights) (Medi-493) Variation Agreement

12/34/56

EX-10.1

from 10-Q 14 pages Patent Licence Agreement (Adair Patent Rights) (Medi-493) Between Celltech Therapeutics Limited and Medimmune Inc

12/34/56

EX-10.1

from 10-Q 3 pages Material contract

12/34/56

EX-10.33

from 10-K 1 page Medimmune, Inc. Summary of Non-Employee Director Compensation

12/34/56